Kisspeptin Peptide: KISS1R Signalling and Fragment Nomenclature

A kisspeptin peptide is discussed here only through molecular and neuroendocrine findings from explicitly identified research models. All material referenced on this page is for laboratory research use only. It is not for human or veterinary use and is not an approved medicinal product. The focus is the KISS1R receptor, its historical name GPR54, and the distinction among fragments called KP-54, KP-14, KP-13 and KP-10. These similar names identify different chain lengths, not interchangeable materials.

Published findings do not describe a commercial batch. Purity can be assessed only batch by batch against the corresponding COA. This overview therefore keeps material identity, experimental model and measured endpoint separate. Introductory context is available in what peptides are and peptide research basics.

From GPR54 to KISS1R

Kotani and colleagues assigned the previously orphan receptor GPR54 to KISS1-derived peptides and examined receptor pharmacology (CHO-K1 cell model and rat model; Kotani 2001, PMID 11457843, DOI 10.1074/jbc.M104847200). Rat and human GPR54 were expressed in that CHO-K1 cell model, and the isolated peptides bound both with low nanomolar affinities; the functional receptor assignment established there is now reflected in the name KISS1R. The separate rat model in the same work refers to an in-vivo observation, where oxytocin secretion was measured after kisspeptin administration (Kotani 2001, PMID 11457843). GPR54 and KISS1R thus name the same kisspeptin receptor, rather than two receptors acting in sequence: the gene originally called GPR54 was renamed KISS1R after that ligand pairing, and the official receptor name recommended by the International Union of Basic and Clinical Pharmacology is the kisspeptin receptor (Kirby 2010, PMID 21079036).

That scope matters. A receptor signal measured in the CHO-K1 cell model demonstrates a response under that assay’s conditions; it does not automatically describe a complete neuronal network or an outcome outside the cell platform. Expression, receptor density, ligand, observation time and readout remain part of the finding.

The review by Pinilla and colleagues synthesised kisspeptin/KISS1R research across experimental levels and placed the system within neuroendocrine regulation (review; Pinilla 2012, PMID 22811428, DOI 10.1152/physrev.00037.2010). A review connects multiple model types but does not replace an individual primary experiment. Interpretation must still show whether evidence came from a cell model, mouse model, human genetic study or human study.

Reading KP-54, KP-14, KP-13 and KP-10

Fragment nomenclature follows the number of amino-acid residues: KP-54 has 54 residues, KP-14 fourteen, KP-13 thirteen and KP-10 ten. The nomenclature review of the International Union of Basic and Clinical Pharmacology describes KP-54 as a C-terminally amidated 54-residue peptide cleaved from the 145-residue gene product, and KP-14, KP-13 and KP-10 as shorter C-terminal cleavage fragments, KP-10 being the smallest active one (review; Kirby 2010, PMID 21079036, DOI 10.1124/pr.110.002774). Kotani and colleagues isolated natural peptides of 54, 14 and 13 residues sharing a common RF-amide C-terminus from human placenta (Kotani 2001, PMID 11457843); the ten-residue chain of that same C-terminal region is designated KP-10, which the later literature describes as the minimal kisspeptin sequence carrying full intrinsic activity (George 2011, PMID 21632807). The shorter labels therefore mark defined chain lengths within one kisspeptin peptide family; they are neither quality grades nor synonyms.

This distinction is central when asking what is kisspeptin in a laboratory record. The family contains kisspeptin peptide fragments of several chain lengths, so an experimental report should identify the fragment actually examined. A reference to a kisspeptin hormone alone leaves the tested fragment unclear because the peptides isolated by Kotani and colleagues already comprise several chain lengths alongside one another (Kotani 2001, PMID 11457843).

Sequence, CAS number and molecular formula are not listed on this overview page, because identity data only carry meaning against the specification of one specific material. For batch-specific documentation, see the Kisspeptin-10 research material reference page. Literature about KP-54 or another fragment does not replace batch-linked analytics for that material.

Signalling through Gq

KISS1R is named a G-protein-coupled receptor in the cited literature (Kotani 2001, PMID 11457843; Shen 2024, PMID 38935498). Its coupling to Gq is described structurally in the cryo-EM work below. Kotani and colleagues specifically measured PIP2 hydrolysis and Ca2+ mobilisation after receptor activation (CHO-K1 cell model; Kotani 2001, PMID 11457843, DOI 10.1074/jbc.M104847200). Those findings describe intracellular readouts in that cell platform.

Shen and colleagues reported cryo-EM structures of KISS1R bound to the endogenous agonist Kisspeptin-10 and to the synthetic analogue TAK-448, and reported a conserved binding mode for both peptides (cryo-EM structures of receptor complexes; Shen 2024, PMID 38935498, DOI 10.1016/j.celrep.2024.114389). The distinctive Gq interaction described there is a property of KISS1R relative to other Gq-coupled receptors, attributed to an angular deviation in its intracellular TM6 region, and not a difference between Kisspeptin-10 and TAK-448. These findings describe the receptor-Gq architecture in those structures; they are not an organism-level endpoint.

A receptor-binding assay, an intracellular signalling assay and a neuronal-activity measurement examine different levels. An early signal can be investigated directly at the expressed receptor in a cell model. Integration into a neuroendocrine network can instead be investigated in a mouse model. No single measurement stands for every level of the kiss1r pathway.

The word “agonist” likewise requires a defined experimental frame. In a cell model, it describes measurable activation of the examined receptor by a ligand. On its own, it quantifies neither binding strength nor signal magnitude in another assay. Comparisons of KP-10 with longer fragments therefore require the same receptor platform, appropriate controls and the same readout. Values from separate experiments are not direct fragment comparisons without methodological harmonisation.

Messager and colleagues examined connections among kisspeptin signals, GPR54 and GnRH neurons (mouse model and sheep model; Messager 2005, PMID 15665093, DOI 10.1073/pnas.0409330102). GPR54 transcripts were colocalised with hypothalamic GnRH neurons, while GnRH neurons appeared anatomically normal in gpr54-deficient animals and showed projections to the median eminence (mouse model). Kisspeptin was administered intracerebroventricularly and GnRH release into the cerebrospinal fluid was then measured directly, with a parallel rise in serum LH (sheep model). The experiments reported there are confined to mouse and sheep preparations. Each result remains bound to its species, preparation, conditions and readout.

What genetics and a human study show

Seminara and colleagues examined GPR54 mutations and supplemented those observations with a separate animal evidence level (human genetic study, COS-7 cell model and Gpr54-deficient mouse model; Seminara 2003, PMID 14573733, DOI 10.1056/NEJMoa035322). The association between receptor variants and the observed neuroendocrine phenotype supported the biological importance of GPR54 in that human genetic study, which examined a consanguineous family lacking pubertal development and one unrelated proband, both with idiopathic hypogonadotropic hypogonadism, rather than a followed cohort. The Gpr54-deficient mouse model supplied a distinct experimental evidence level, and wild-type versus mutant GPR54 constructs were additionally compared in transfected COS-7 cells. Neither evidence level characterises an offered research material.

George and colleagues administered Kisspeptin-10 intravenously to healthy male volunteers, both as bolus doses and as a continuous infusion, and determined LH pulse frequency by deconvolution analysis during the infusion arm (human study; George 2011, PMID 21632807, DOI 10.1210/jc.2011-0089). The measured change was a study-bound physiological research finding in that human study. It is not a claim, a product property or transferable beyond the specific study setting. Test substance, population, study design, timing and endpoint must be read together.

These evidence levels answer different questions. Receptor pharmacology is isolated in a cell model. A signal is observed within an organismic context in a mouse model. Variants are associated with a phenotype in a human genetic study. A predefined measurement is recorded under controlled conditions in a human study. They do not establish a general hierarchy of outcomes.

Limits of mechanistic interpretation

A kisspeptin peptide finding is imprecise without its fragment and model. A KP-54 finding cannot be presented as an identical KP-10 finding solely because the fragments share a C-terminus. Likewise, a receptor signal in a cell model cannot become a neuronal or organismic endpoint without intermediate evidence. Any comparison must document fragment identity, assay concentration, receptor expression, species, tissue and measurement method.

An experimental plan should therefore define the fragment, model, controls and endpoint before interpreting a paper. Guidance on in vitro and in vivo study models helps keep these evidence types distinct. Original publications and documentation for the specific batch remain separate from this overview.

Sources